Do Gulf Toadfish Use Pulsatile Urea Excretion to Chemically Communicate Reproductive Status?

Gulf toadfish (Opsanus beta) are exceptionally capable of switching from excreting ammonia as their primary nitrogenous waste to excreting predominantly urea in distinct pulses across the gill. Previous studies suggest that these urea pulses may be used for intraspecific chemical communication. To determine whether pulsatile urea excretion communicates reproductive status, toadfish were sexed using ultrasound and delivered conspecific-conditioned seawater (CC-SW) that previously housed a conspecific of the opposite sex, a conspecific chemical alarm cue (avoidance control), or a prey cue (attraction control). Swim behavior, attraction to or avoidance of the cues, and changes in the pattern of pulsatile urea excretion were monitored during and after delivery. Gulf toadfish did not spend more time in zones that were delivered CC-SW or prey cue. However, male toadfish spent significantly more time swimming after the delivery of female cues than control seawater (SW). In contrast, toadfish did not appear to have an immediate avoidance response to the conspecific alarm cue. Additionally, significantly more toadfish pulsed within 7 h of CC-SW and prey cue delivery compared to control SW, and pulse frequency was 1.6 times greater in response to CC-SW than control SW. These results, in combination with increased urea production and excretion the during breeding season, suggest that toadfish may use pulsatile urea excretion to communicate with conspecifics when exposed to chemosensory cues from the opposite sex

Single-Cell Analysis Reveals Distinct Gene Expression and Heterogeneity in Male and Female Plasmodium falciparum Gametocytes

© 2018 Walzer et al. Sexual reproduction is an obligate step in the Plasmodium falciparum life cycle, with mature gametocytes being the only form of the parasite capable of human-to-mosquito transmission. Development of male and female gametocytes takes 9 to 12 days, and although more than 300 genes are thought to be specific to gametocytes, only a few have been postulated to be male or female specific. Because these genes are often expressed during late gametocyte stages and for some, male- or female-specific transcript expression is debated, the separation of male and female populations is technically challenging. To overcome these challenges, we have developed an unbiased single-cell approach to determine which transcripts are expressed in male versus female gametocytes. Using microfluidic technology, we isolated single mid- to late-stage gametocytes to compare the expression of 91 genes, including 87 gametocyte-specific genes, in 90 cells. Such analysis identified distinct gene clusters whose expression was associated with male, female, or all gametocytes. In addition, a small number of male gametocytes clustered separately from female gametocytes based on sex-specific expression independent of stage. Many female-enriched genes also exhibited stage-specific expression. RNA fluorescent in situ hybridization of male and female markers validated the mutually exclusive expression pattern of male and female transcripts in gametocytes. These analyses uncovered novel male and female markers that are expressed as early as stage III gametocytogenesis, providing further insight into Plasmodium sex-specific differentiation previously masked in population analyses. Our single-cell approach reveals the most robust markers for sex-specific differentiation in Plasmodium gametocytes. Such single-cell expression assays can be generalized to all eukaryotic pathogens

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ):Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.</p